IL33 and deep vein thrombosis: In vitro and in vivo experiments showed that MkL assumed and managed antigenic proteins and pathogens, stimulated CD4+T cell triggering in an MHC II-dependent modality [72] and may have a central role in IL-33-induced thrombosis in COVID 19 patients.